[1]侯艳军,张秋怡,单志娟,等.多发性骨髓瘤患者骨髓中CD56和CD117水平表达对评估疾病预后的价值[J].现代检验医学杂志,2021,36(06):74-77.[doi:10.3969/j.issn.1671-7414.2021.06.015]
　HOU Yan-jun,ZHANG Qiu-yi,SHAN Zhi-juan,et al.Significance of the Expression of CD56 and CD117 in Evaluating the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(06):74-77.[doi:10.3969/j.issn.1671-7414.2021.06.015]
点击复制

多发性骨髓瘤患者骨髓中CD56和CD117水平表达对评估疾病预后的价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年06期
页码:
74-77
栏目:
论　著
出版日期:
2021-12-15

文章信息/Info

Title:
Significance of the Expression of CD56 and CD117 in Evaluating the Prognosis of Patients with Multiple Myeloma
文章编号:
1671-7414（2021）06-074-04
作者:
侯艳军1; 张秋怡2; 单志娟1; 郜伟峰1; 周合冰1
（1.首都医科大学附属北京潞河医院血液科,北京 101149；2.内蒙古科技大学包头医学院基础医学与法医学院，内蒙古包头 014040）
Author(s):
HOU Yan-jun;  ZHANG Qiu-yi;  SHAN Zhi-juan;  et al
（1.Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China; 2.School of Basic Medicine and Forensic Medicine, Baotou Medical College, Inner Mongolia University of Science and Technology，Inner Mongolia Baotou 014040 ,China）
关键词:
多发性骨髓瘤;  白细胞分化抗原56;  白细胞分化抗原117
分类号:
R733.3；R730.43
DOI:
10.3969/j.issn.1671-7414.2021.06.015
文献标志码:
A
摘要:
目的　探讨多发性骨髓瘤(multiple myeloma，MM)患者CD56和CD117表达在疾病预后评估中的价值。方法　选取2019年12月～2020年12月首都医科大学附属北京潞河医院32例初诊MM患者，根据骨髓中CD56和CD117表达，分为CD56+CD117+，CD56+CD117-，CD56-CD117+和CD56-CD117-四组，分别检测各组骨髓瘤细胞数、M蛋白含量和细胞遗传学结果；采用单因素方差分析CD56，CD117表达与骨髓瘤细胞数量、细胞遗传学结果在疾病预后判断中的意义。结果　CD56和CD117阳性率分别为62.5%和33.3%。CD56-CD117-组骨髓瘤细胞为36.6%±23.9%明显高于其他三组（5.5%±2.8%，12.1%±7.3%，24.4%±5.9%），差异有统计学意义（F=4.061，P=0.022）。TP53阳性率在CD56-组（25%）显著高于CD56+组（14.3%），差异有统计学意义（χ2=3.854，P=0.04）。CD117+组与CD117-组相比，TP53，1q21+，IGH融合阳性率比较差异无统计学意义（χ2=0.323~2.677，均P>0.05）。TP53和CCDN1/IGH阳性率在CD56-CD117-组（33.3%和50.0%）明显高于CD56+CD117+组（20.0%和40.0%）和CD56+CD117-组（11.1%和33.3%）差异均有统计学意义（χ2=6.036~14.579，均P<0.05）。结论　CD56-和CD117-MM患者肿瘤负荷较高，并且出现TP53缺失、CCND1/IGH融合和复杂核型等细胞遗传学异常风险较高，预后较差。
Abstract:
Objective　To investigate the expression of CD56 and CD117 in patients with multiple myeloma (MM), and evaluate its value in clinical prognosis judgment. Methods　A total of 32 cases of newly diagnosed multiple myeloma in the Department of Hematology, Beijing Luhe Hospital of Capital Medical University from December 2019 to December 2020 were enrolled this study. According to the expression of CD56 and CD117, they were divided into 4 groups: CD56+CD117+，CD56+CD117-，CD56-CD117+ and CD56-CD117-. The number of plasma cells and M protein type and content were detected. Single factor variance was used to analyze the relationship between CD56, CD117, myeloma cells, and cytogenetics in disease diagnosis and prognosis. Results　 The positive of CD56 and CD117 was 62.5% and 33.3%. Myeloma cells in CD56-CD117-group 36.6%±23.9% was much higher than the other three group（5.5%±2.8%，12.1%±7.3%，24.4%±5.9%）, the difference statistically significant(F=4.061，P=0.022). Comparison with CD56- patients, the incidence of TP53 was significantly lower in CD56+ patients（25% vs14.3%）, the difference statistically significant（χ2=3.854，P=0.04）. Compared with CD117-, the positive rate of TP53, 1q21+ and IGH translocation was not significantly different (χ2=0.323~2.677, all P>0.05). The positive rates of TP53 and CCND1/IGH in the CD56-CD117- group （33.3%，50%）were significantly higher than those in the CD56+CD117+ （20.0%，40%）and CD56+CD117- groups（11.1%，33.3%）, the difference statistically significant (χ2=6.036~14.579, all P<0.05). Conclusion　CD56- and CD117- patients had higher tumor burden and much higher risk of cytogenetic abnormalities such as TP53, CCND1/IGH, complex karyotype, and the worse prognosis.

参考文献/References:

[1] 朱婉秋，陈文明．IMWG 多发性骨髓瘤诊断标准解读[J]. 临床血液学杂志, 2017, 30(7): 507-509.ZHU Wanqiu, CHEN Wenming. Unscramble thediagnostic criteria for multiple myeloma revised byIMWG [J]. Journal of Clinical Hematology, 2017,30(7): 507-509.
[2] 侯健，傅卫军．多发性骨髓瘤及其相关疾病[M]．上海：上海科学技术出版社，2002：6-10．HOU Jian, FU Weijun. Multiple myeloma andrelated diseases[M]. Shanghai: Shanghai Science andTechnology Press, 2002: 6-10.
[3] YOSHIDA T, RI M, KINOSHITA S, et al. Lowexpression of neural cell adhesion molecule, CD56,is associated with low efficacy of bortezomib plusdexamethasone therapy in multiple myeloma[J]. PLoSOne, 2018, 13(5): e0196780.
[4] 时杰, 孙恺, 朱尊民, 等.CD56 和( 或)CD117 表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义[J]. 中华血液学杂志, 2019,40(8): 693-696.SHI Jie, SUN Kai, ZHU Zunmin, et al. Prognosticsignificance of CD56 and CD117 expression in patientswith newly diagnosed multiple myeloma treated withbortezomib-based first-line therapy [J]. Chinese Journalof Hematology, 2019, 40(8): 693-696.
[5] BATAILLE R, PELLAT-DECEUNYNCK C, ROBILLARDN, et al. CD117 (c-kit) is aberrantly expressedin a subset of MGUS and multiple myeloma with unexpectedlygood prognosis[J]. Leukemia Research, 2008,32(3): 379-382.
[6] PAN Ying, WANG Huiping, TAO Qianshan, et al.Absence of both CD56 and CD117 expression onmalignant plasma cells is related with a poor prognosisin patients with newly diagnosed multiple myeloma[J].Leukemia Research, 2016, 40(1): 77-82.
[7] 孙卫红，王清涛，翟玉华，等．多发性骨髓瘤遗传学研究进展[J]. 现代检验医学杂志,2007,22(6):16-19.SUN Weihong, WANG Qingtao, ZHAI Yuhua, et al.Cytogenetics abnormalities of multiple myelomareview[J]. Journal of Modern Laboratory Medicine,2007, 22(6): 16-19.
[8] 江红. 多发性骨髓瘤实验室诊断与进展[J]. 中华实用诊断与治疗杂志, 2010, 24(11): 1043-1045.JIANG Hong. Laboratory diagnosis and progress ofmultiple myeloma[J]. Journla of Chinese PracticalDiagnosis and Therapy, 2010, 24(11): 1043-1045.
[9] 刘玉霞, 胡国瑜, 袁朝晖, 等.CD269 和CD317 在多发性骨髓瘤中的表达及临床意义[J]. 现代检验医学杂志, 2018,33 (2): 58-61.LIU Yuxia, HU Guoyu, YUAN Zhaohui, et al.Expression of CD269 and CD317 in multiple myelomaand its clinical significance [J]. Journal of ModernLaboratory Medicine, 2018,33 (2): 58-61.
[10] 何进, 张艳, 申娴娟, 等. 多发性骨髓瘤患者血清可溶性PD-L1 水平在辅助诊断及临床分型的价值研究[J]. 现代检验医学杂志,2021,36(2):15-18,110.HE Jin, ZHANG Yan, SHEN Xianjuan,et al. Value ofblood soluble PD-L1 in the auxiliary diagnosis andclinical subtype of multiple myeloma [J].Journal ofModern Laboratory Medicine,2021,36(2):15-18,110.
[11] 张琼丽, 史敦云, 李玉珠, 等. 多发性骨髓瘤细胞流式细胞术检测方法研究[J]. 中国卫生检验杂志,2010,20(11):2861-2863.ZHANG Qiongli, SHI Dunyun, LI Yuzhu, et al. Studyon the method of examining multiple myeloma cellswith flow cytometry [J]. Chinese Journal of HealthLaboratory Technology, 2010, 20(11): 2861-2863.
[12] 邱荃, 朱平, 王茫桔, 等. 初诊多发性骨髓瘤患者CD56 和CD19 表达与染色体核型及预后的关系[J].中国实验血液学杂志, 2016, 24(4): 1071-1078.QIU Quan, ZHU Ping, WANG Mangju, et al.Expression of CD56 and CD19 in patients with newlydiagnosed multiple myeloma and their relationship withkaryotypes and prognosis [J]. Journal of ExperimentalHematology, 2016, 24(4): 1071-1078.
[13] 中华医学会血液学分会实验诊断血液学学组．血液病细胞- 分子遗传学检测中国专家共识(2013 年版)[J]. 中华血液学杂志,2013,34(8):733-736.Hematology Society of Chinese Medical Association,Laboratory Diagnosis Group. Consensus of Chineseexperts on cytogenetics and molecular genetic analysisfor the diagnosis of hematologic disorders (2013) [J].Chinese Journal of Hematology, 2013, 34(8): 733-736.
[14] 孙琦, 安刚, 刘恩彬, 等．31 例细胞周期蛋白D1 基因阳性多发性骨髓瘤患者的临床及骨髓病理学特征分析[J]. 中华血液学杂志,2015,36(9):775-779.SUN Qi, AN Gang, LIU Enbin, et al. The clinic andpathologic significance of plasma cell myeloma withCCND1[J]. Chinese Journal of Hematology, 2015,36(9): 775-779.
[15] 周铁成，秦庆，杨小云，等．免疫固定电泳在多发性骨髓瘤的临床应用[J]．现代检验医学杂志,2007，22(2):68-69.ZHOU Tiecheng, QIN Qing, YANG Xiaoyun, et al.Clinical application of immunofixation electrophoresisin multiple myeloma[J]. Journal of Modern LaboratoryMedicine, 2007,22(2):68-69.
[16] 朱平. 应用骨髓细胞免疫表型分析诊断和监测多发性骨髓瘤[J]. 中华检验医学杂志, 2011, 34(1): 2-4.ZHU Ping. Application of bone marrow cell immunophenotypinganalysis in diagnosing and monitoring ofmultiple myeloma[J]. Chinese Journal of LaboratoryMedicine, 2011, 34(1): 2-4.
[17] SAHARA N, TAKESHITA A. Prognostic significanceof surface markers expressed in multiple myeloma:CD56 and other antigens[J]. Leukemia & Lymphoma,2004, 45(1): 61-65.
[18] SKERGET M, SKOPEC B, ZADNIK V, et al. CD56expression is an important prognostic factor in multiplemyeloma even with bortezomib induction[J]. ActaHaematologica, 2018, 139(4): 228-234.
[19] 刘彦, 克晓燕, 王晶, 等. 伴17P 缺失的多发性骨髓瘤患者的临床特征和治疗反应[J]. 中国实验血液学杂志,2017, 25(3): 802-806.LIU Yan, KE Xiaoyan, WANG Jing, et al. Clinicalfeatures and response to treatment in newly diagnosedmultiple myeloma patients with deletion 17P [J]. Journalof Experimental Hematology, 2017, 25(3): 802-806.
[20] 翟冰，邹丹丹，闫建军，等．荧光原位杂交检测117 例多发性骨髓瘤细胞遗传学异常及预后分析[J].中国实验血液学杂志, 2016, 24(1): 127-130.ZHAI Bing, ZOU Dandan, YAN Jianjun, et al.Cytogenetic abnormalities and outcomes of 117 patientswith multiple myeloma detected by FISH [J]. Journal ofExperimental Hematology, 2016, 24(1): 127-130.
[21] NARITA T, INAGAKI A, KOBAYASHI T, et al. t(14;16)-positive multiple myeloma shows negativity for CD56expression and unfavorable outcome even in the era ofnovel drugs[J]. Blood Cancer Journal, 2015, 5(2): e285.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(06):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(06):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(06):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(06):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(06):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(06):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(06):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[9]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(06):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[10]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(06):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]

更新日期/Last Update: 1900-01-01